Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
Status:
Completed
Trial end date:
2015-04-24
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess whether a locally-administered rhBMP-2/CPM
injection can rapidly increase bone mass in subjects at high risk for osteoporotic fractures
of the hip. All subjects will receive standard treatment for low bone mass, consisting of
bisphosphonates, calcium, and vitamin D (all taken by mouth). Subjects that are randomly
selected to receive treatment with rhBMP-2 will receive an injection directly into the hip.
The injection is given in a surgery room using a light anesthesia.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Calcium Calcium, Dietary Diphosphonates Ergocalciferols Vitamin D Vitamins